BioWorld - Friday, December 26, 2025
To read the full article sign up for free or sign in.
Hightide’s HTD-1801 outperforms Farxiga in type 2 diabetes
Dec. 2, 2025
By Tamra Sami
Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met the primary endpoint showing superior improvements in key cardiometabolic markers in patients with type 2 diabetes compared to Astrazeneca plc’s SGLT2 inhibitor, Farxiga (dapagliflozin), in a head-to-head phase III trial.
BioWorldBioWorld AsiaClinicalEndocrine/metabolicAsia-PacificChinaNMPA